account_balance
Investment manager · 13F filer · SEC CIK 2043476
B Group, Inc.
Reported value$176Mas of Jun 30, 2026
Positions18 1 new, 3 sold out
Top 10 weight79.2%ADMA alone is 15%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ADMAAdma Biologics Inc
15.5%
PALIPalisade Bio Inc
13.5%
NRXPNRX Pharmaceuticals Inc
9.5%Added +36%
FTHFaeth Therapeutics Inc
8.7%New
TSHATaysha Gene Therapies Inc
7.0%
PRAXPraxis Precision Medicines I
6.3%
CLLSCellectis S A
5.6%
ZLABZai Lab Ltd
4.9%
GPCRStructure Therapeutics Inc
4.3%Added +10%
ORKAOruka Therapeutics Inc
4.1%
IOVAIovance Biotherapeutics Inc
3.5%
SYRESpyre Therapeutics Inc
3.5%Trimmed −30%
ADMAAdma Biologics Inc
15.5%
PALIPalisade Bio Inc
13.5%
NRXP9.5%FTH8.7%TSHA7.0%PRAX6.3%CLLS5.6%ZLAB4.9%GPCR4.3%ORKA4.1%IOVA3.5%SYRE3.5%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ADMA Adma Biologics Inc 15.5% HeldPALI Palisade Bio Inc 13.5% HeldNRXP NRX Pharmaceuticals Inc 9.5% Added +36%FTH Faeth Therapeutics Inc 8.7% NewTSHA Taysha Gene Therapies Inc 7.0% HeldPRAX Praxis Precision Medicines I 6.3% HeldCLLS Cellectis S A 5.6% HeldZLAB Zai Lab Ltd 4.9% HeldGPCR Structure Therapeutics Inc 4.3% Added +10%ORKA Oruka Therapeutics Inc 4.1% HeldIOVA Iovance Biotherapeutics Inc 3.5% HeldSYRE Spyre Therapeutics Inc 3.5% Trimmed −30%
What changed